David joined Quest Diagnostics in 2015 as the General Manager, Information Ventures. In this position David and his team have been focused on advancing Quest’s strategy, solutions and partnerships in the area of clinical informatics. Powered by a clinical data repository with over 48 billion lab results, connectivity to half of the country’s physicians and hospitals via over 650 EMR interfaces, over 400,000 patient touch points a day, and broad geographic reach via over 2000 Patient Service Centers and 15,000 mobile care professionals, Information Ventures is delivering analytics solutions across the care and therapeutic continuums. David has more than 25 years of experience in healthcare technology innovation with a number industry leading companies, from the life science research bench to the patient’s bedside. His positions of increasing responsibility include serving as Vice President of Marketing at both Philips Healthcare and Becton Dickinson, Chief Marketing Officer at GE Healthcare – Patient Monitoring Solutions, General Manager at GE Healthcare - Patient Parameters Segment, and Senior Vice President of Marketing and Operations at Convergence Medical Devices. David has also been involved in a number of start-up companies in healthcare and technology. David earned an MBA from Northeastern University’s High Technology Management program, an MA in Communications from Emerson College and a BA from Vassar College.
Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informing for the process from discovery to new indications, clinical trial design and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE data to better understand the patient populations using their drugs and the respective outcomes and to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support.